US – Due to the rapid mutation of the virus, the vaccine needs to counter an immune response against a variety of strains of HIV, the authors of the study published in the journal Science Translational Medicine.

 Immunogens developed to fight HIV successive attacking multiple targets have failed to stop the reproduction of broadly neutralizing antibodies.

Therefore, the study led by Dr. Zhang Ruijun, Duke University, said that the focus should focus precisely on these broadly neutralizing antibodies, which are controlled by HIV.

This was demonstrated in research conducted in mice and macaques, in which researchers found identical results in trials with both animals.

A successful HIV vaccine needs to overcome all the mechanisms of immune tolerance, a field in which much remains pending investigation, Zhang lamented.

The human immunodeficiency virus (HIV) attacks the immune system and weakens surveillance and defense against infections and some cancers.

As it destroys immune cells and alters its function, the infected person is gradually becoming immunodeficient.

Acquired immunodeficiency syndrome (AIDS) is the most advanced stage of infection.

According to the World Health Organization, HIV remains a major problem on the planet, having claimed more than 34 million lives so far. Eradicating the disease in 2030 is the main objective of the United Nations.